ImmunityBio Profit Margin

The latest profit margin for IBRX is -6.06% as of March 2026. That compares with -13.17% in the prior-year period — up 54.0% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside ImmunityBio's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBRX's profit margin moved from -13.17% to -6.06% — a 54.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ImmunityBio's valuation or profitability profile.

Against Healthcare companies, IBRX currently prints -6.06% for profit margin, while the sector average sits near 15.52%. That is roughly 4005.6% below the sector mean. Large gaps often invite a closer look at ImmunityBio's growth, margins, and balance sheet.

Profit Margin shows how effectively ImmunityBio converts resources into returns. At -6.06%, IBRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -13.17% in the prior-year period — up 54.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IBRX's profit margin (-6.06%), review year-over-year change from -13.17%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.